Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …
Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …
Although Pfizer beat Sarepta to start a Phase 3 trial of its gene therapy, the smaller biotech is claiming a milestone in initiating the study …
